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Early genome-wide association (GWA) studies on Parkinson’s disease (PD) have not been able to 
yield conclusive, replicable signals of association, perhaps due to limited sample size. We aimed 
to investigate whether association signals derived from the meta-analysis of the first two GWA 
investigations might be replicable in different populations. We examined six single-nucleotide 
polymorphisms (SNPs) (rs1000291, rs1865997, rs2241743, rs2282048, rs2313982, and 
rs3018626) that had reached nominal significance with at least two of three different strategies 
proposed in a previous analysis of the original GWA studies. Investigators from the “Genetic 
Epidemiology of Parkinson’s Disease” (GEOPD) consortium were invited to join in this study. 
Ten teams contributed replication data from 3,458 PD cases and 3,719 controls. The data from the 
two previously published GWAs (599 PD cases, 592 controls and 443 sibling pairs) were 
considered as well. All data were synthesized using both fixed and random effects models. The 
summary allelic odds ratios were ranging from 0.97 to 1.09 by random effects, when all data were 
included. The summary estimates of the replication data sets (excluding the original GWA data) 
were very close to 1.00 (range 0.98–1.09) and none of the effects were nominally statistically 
significant. The replication data sets had significantly different results than the GWA data. Our 
data do not support evidence that any of these six SNPs reflect susceptibility markers for PD. 
Much stronger signals of statistical significance in GWA platforms are needed to have substantial 
chances of replication. Specifically in PD genetics, this would require much larger GWA studies 
and perhaps novel analytical techniques.
Keywords
Parkinson’s disease; meta-analysis; genome-wide association
INTRODUCTION
Genome-wide screening for genetic associations is a promising approach for the exploration 
of the relationship between the genetic determinants and common complex diseases 
[McCarthy et al., 2008]. Meta-analysis is a technique that entails the combination of 
different studies or data sets. Recently, it has become a powerful tool for the synthesis of 
different genome-wide association (GWA) studies for the same phenotype [Evangelou et al., 
2007; Baum et al., 2008; Zeggini et al., 2008]. The first attempt to synthesize results from 
GWA studies has been performed for the genetics of Parkinson’s disease (PD) [Evangelou et 
al., 2007]. The effect estimates from a two-tier design study (LEAPS) [Maraganore et al., 
2005] and from a single-tier design (NINDS) [Fung et al., 2006] study were synthesized to 
identify potentially significant signals. Given the limited sample sizes of both combined 
GWA data sets, the attained statistical significance for the summary results were not 
impressive. Nevertheless, some tentative signals were noted and six single-nucleotide 
polymorphisms (SNPs) were found to be nominally significant at the P <0.05 level even by 
random effects calculations with at least two of the three meta-analytic strategies that were 
investigated.
The replication of the findings from GWAs and the detection of loci with realistic effect 
sizes require the use of large sample sizes [Burton et al., 2008]. In order to assess if the 
signals from the meta-analysis reflect true findings, we co-ordinated an independent large-
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scale multicenter international replication effort. Our study incorporated also data from the 
previous published GWAs [Maraganore et al., 2005; Fung et al., 2006] along with the 
replication data. Meta-analytical techniques were applied for the combination of the 
available data.
METHODS
Study Population
Investigators consisting the “Genetic Epidemiology of Parkinson’s Disease” (GEOPD) 
consortium were invited to join in this study. Ten teams participated in the replication study, 
contributing with individual-level data on PD cases and PD-free controls. Data from the two 
already published GWAs were also available for comparison with the replication data and 
for inclusion in the overall analysis.
Polymorphisms
The following six polymorphisms were evaluated: rs1000291, rs1865997, rs2241743, 
rs2282048, rs2313982, and rs3018626. These SNPs had been found to have nominally 
statistical significant association even by random effects calculations, in at least two of the 
three strategies used for the combination of data from the first two published GWA studies: 
enhancement of first-stage data, enhancement of replication data, and joint analysis of all 
available data sets [Evangelou et al., 2007]. Three of the six had nominally significant 
results with all three strategies and no or minimal heterogeneity (I2 0–15%) across the 
combined data sets. The summary data from the combined GWA data sets for these six 
polymorphisms in the joint analysis varied from 0.76 to 0.81 (for protective effects) and 1.25 
to 1.65 (for susceptibility effects) by fixed effects and from 0.76 to 0.80 and 1.25 to 1.67 by 
random effects analyses. P-values ranged from 0.0001 to 0.004 by fixed effects and from 
0.0001 to 0.038 by random effects.
Genotyping of DNA samples was undertaken either on-site or through commercial contract. 
Methods that were used was fluorescence polarization single-base extension (Wirdefeldt), 
allelic discrimination (real-time PCR) (Tan), mass spectrometry (van Broeckhoven), 
TaqMan assay (Hadjigeorgiou, Ferrarese, Annesi), Illumina genotyping chips (Illumina 
Humanhap550) (Sharma), Sequenom Platform (Mellick), direct sequencing (Brice), and 
Illumina Golden Gate assay (Elbaz).
For teams where the genotyping call rate was <95%, we requested a second effort to 
genotype the missing samples, so that the 95% threshold could be exceeded for 
completeness of genotyping information. We also used an exact test to examine whether 
there is a deviation from the Hardy–Weinberg equilibrium (HWE) among controls in each 
team. Deviation for HWE was deemed significant for P-value <0.05. In the presence of 
significant deviation from HWE, the specific teams were also asked to consider re-
genotyping their samples. We specified upfront that we would perform for each SNP 
sensitivity analyses that would exclude data from teams where the missing rate was >5% or 
there was nominally significant deviation from HWE in the controls.
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Data Synthesis
The natural log odds ratio and their respective standard errors were calculated for each 
evaluated SNP within each team. For consistency, we computed all the effect estimates 
based on the major versus minor allele contrast. Assignment of minor allele was based on 
the allele frequencies of the control samples in the NINDS GWA study. Then the log ORs 
were synthesized using both fixed [Lau et al., 1997] and random effects models 
[DerSimonian and Laird, 1986]. In fixed effects models, it is assumed that the risk of the 
alleles is always the same across the comparisons. In random effects models, the risk is 
varying around an overall average. Thus, random effects models can be considered more 
conservative. In absence of heterogeneity, summary effects obtained from fixed and random 
effects models coincide. We tested the presence of between-study heterogeneity using 
Cochran’s Q test and we calculated the extent of inconsistency using I2, which ranges from 
0% to 100% [Higgins and Thompson, 2002; Higgins et al., 2003]. We also calculated 95% 
confidence intervals for I2 [Ioannidis et al., 2007].
In the main analysis, all the effect estimates from the replication effort and the published 
GWA studies were considered. Another analysis was also undertaken where summary 
effects were provided separately for replication and already published data. Even for 
genuine associations, it is expected that effect sizes may be inflated in the discovery (GWA) 
phase [Zollner and Pritchard, 2007] [Ioannidis, 2008b] and this may result in heterogeneity 
in the data when both the GWA and replication data are considered.
As above, in a sensitivity analysis we excluded studies that deviated from HWE and studies 
that had genotyping call rate < 95% in cases or in controls groups only.
We calculated the Bayes factor for nominally significant associations (uncorrected for 
multiple comparisons), considering a spike and smear prior [Ioannidis, 2008a] and assuming 
that average effect sizes for associations in PD may reflect odds ratios of 1.3. Bayes factor 
evaluates if a nominally statistically significant result increases the credibility of a 
postulated association.
The six evaluated SNPs were very common with minor allele frequencies ranging from 
22.7% to 49.3% in the combined GWA data sets, with one exception (rs2313982) where the 
minor allele frequency was only 9.4%. For the lowest minor allele frequency among them, 
odds ratios of 1.25 would require almost 6,800 cases and controls to have 80% power to 
replicate at alpha =0.05, and about 10,450 cases and controls to have 80% power to replicate 
at alpha =0.05/6 =0.0083, assuming 1:1 allocation and homogeneous effects. For minor 
allele frequencies of 22.7%, the respective numbers are 3,400 and 5,240 cases and controls 
for odds ratios of 1.25 for P =0.05 and 0.0083, respectively. For odds ratios of 0.8, the 
respective numbers are 3,840 cases and controls for P =0.05 and 5,920 cases and controls 
for P =0.0083.
All analyses were performed with Intercooled Stata 10 (College Station, TX).
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RESULTS
Characteristics of Participating Studies
Ten replicating teams contributed 3,458 cases and 3,719 controls. Characteristics of these 10 
study populations are shown in Table I. The previously published GWAs included (a) 443 
sibling pairs (family-based design) (cases were enrolled at the Department of Neurology of 
the Mayo Clinic in Rochester, MN, and their siblings were contacted, if permitted, in order 
to exclude Parkinsonism via a validated tool) and 332 matched case-unrelated control pairs 
(LEAPS, two-tier design) [Maraganore et al., 2005] and (b) 267 publicly available samples 
from a cohort of PD patients and 270 neurologically normal controls (NINDS, single-tier 
design) with publicly available samples [Fung et al., 2006].
Analysis Including All Data
Allele frequencies per team and per SNP of interest are shown in Table II. The meta-
analysis of these data did not reveal any nominally statistically significant associations by 
random effects with the exception of rs3018626. The summary OR for this SNP was 1.09 
(95% CI 1.01–1.17) with P =0.037 uncorrected for multiple comparisons (Table II). With 
fixed effects analysis the summary estimate for the specific SNP was also nominally 
statistically significant (P =0.032 uncorrected) and low heterogeneity was observed (I2 =6%) 
(Table II).
In two cases, one study deviated from HWE equilibrium in the control group (Brice for 
rs3018982 and Annesi for rs2282048 [P <0.0001 and 0.02, respectively]). Moreover, in six 
studies even though the overall genotyping call rate was >95%, more than 5% missing 
genotypes existed in the control group. We performed a sensitivity analysis excluding these 
studies and the results were essentially unaltered (Table III). For rs2313982, a nominally 
statistically significant association was detected (OR =1.15) (95% CI 1.02–1.31) (P =0.026, 
uncorrected for multiple corrections), but moderate heterogeneity was observed. The 
observed association was not nominally significant with random effects analysis (Table II).
None of the aforementioned nominally significant associations revealed with either main or 
sensitivity analyses would remain significant after adjusting even for six tested SNPs.
Analysis Including Only Replication Studies
All summary effects obtained from the replication effort were very close to unity (Fig. 1) 
with estimated summary ORs ranging from 0.98 to 1.09 with random effects analyses. None 
of the effects were nominally statistically significant. Also, no heterogeneity was observed 
in three SNPs (rs2241743, rs2313982, and rs3018626 with I2 ranging from 0% to 6%), 
whereas moderate to large heterogeneity was observed for the other three SNPs under study 
(rs1000291, rs1865997, and rs2241743) with I2 ranging from 49% to 67%.
The summary effects obtained from the replication data were statistically significantly 
different from the results of the synthesis of the GWA data. Four out of six SNPs 
(rs1000291, rs1865997, rs2241743, and rs2282048) had summary effects that were even in 
the opposite direction compared to summary effects obtained from the original GWA data.
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Bayes Factor and Credibility of the Association
We calculated the Bayes factors for the association between rs3018626 and PD that was 
nominally statistically significant when all data were included. For an expected OR =1.3, the 
−log10 Bayes factor is 0.01. This means that the probability of the association being true 
does not increase given the observed data, compared with what we thought before obtaining 
these data.
DISCUSSION
Our analysis of six SNPs suggested by a meta-analysis of two GWA data sets does not show 
any convincing associations with PD. None of the SNPs under study reached even nominal 
significance in the replication data sets and inclusion of all data (including the GWA 
discovery data) yielded only one SNP with a P-value of 0.037, which should be dismissed 
given the extreme multiplicity of the agnostic discovery approach in the GWA setting. The 
Bayes factor for the combined data was not supportive of an association being present.
The collaborative analysis has sufficient power to detect modestly small associations for five 
of the six tested SNPs. However, this would not be the case for very subtle associations. For 
example, effects in the range of odds ratios of <1.12 may have been missed, and experience 
from meta-analysis of GWA in type 2 diabetes (T2D) suggests that such effects cannot be 
excluded [Zeggini et al., 2008]. On the other hand, we managed to assemble one of the 
largest studies in the history of PD research. Perusal of very subtle effects, if any such exist, 
would really require full exploitation of all available samples from multiple consortia 
[Seminara et al., 2007]. Moreover, if diagnostic criteria and patient characteristics create 
genuine heterogeneity in the genetic effects, replication would be difficult or even 
impossible even with extremely large sample sizes [Mooneshinghe et al., 2008]. Power may 
also be diluted by genotyping errors and unfortunately we were not able to perform central 
genotyping or central assessment/quality control for the assessment of genotyping errors. 
Nevertheless, while genuine heterogeneity and genotyping errors can never be totally 
excluded, we doubt that they primarily explain the non-replication in the observed results.
The most likely explanation for our findings is that none of these six SNPs has a genuine 
association with PD risk. Even when combined, the two GWAs remain underpowered to 
reveal efficiently true markers with modest effects. Moreover, testing only six SNPs is 
unlikely to have hit genuine markers for PD susceptibility. Due to resource constrains, we 
could not evaluate a wider range of SNPs that might have been more informative. It is 
expected that genuine associations are not on the very top of the list in the data that arise 
from GWA studies, regardless of the selection analytical strategy [McCarthy et al., 2008]. 
Moreover, we should acknowledge that one SNP (rs2313982) has been further evaluated 
with published data before, and this information is widely available at www.pdgene.org. 
This database provides a comprehensive assessment of all prior genetic association studies 
in PD. Analysis of this SNP shows nominally statistically significant random effects odds 
ratios in the PDGene meta-analyses after exclusion of the initial study (P =0.012). However, 
both main and sensitivity analyses by random effects did not show any statistical significant 
results in our sample. An informal meta-analysis of previous data (excluding the first data) 
plus our new data (excluding previously published information) by random effects would 
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give an odds ratio of 1.08 (95% CI 1.01–1.17), which is not nominally significant (P =0.055, 
no between-study heterogeneity, I2 =0, 95% CI 0–45%).
Given our current experience, and the recurrent inability to replicate top hits derived from 
modest size GWA data sets [Elbaz et al., 2006], we believe that a more extensive list of 
candidate markers for replication should await the accumulation of much larger sample sizes 
from GWA platforms. Additional GWA studies are currently being completed on PD and 
their data would be very useful to combine with the existing information. Given that 
different platforms are used in these GWA investigations, imputation of polymorphisms that 
are not directly typed [Marchini et al., 2007] can enhance also the genome coverage 
compared with the first meta-analysis of GWA data that was limited only to common, 
overlapping polymorphisms across Perlegen and Illumina platforms [Evangelou et al., 
2007]. Concurrently, novel analytical approaches, such as pathways analyses [Lesnick et al., 
2007; Wang et al., 2007; Li et al., 2008; Srinivasan et al., 2008], and extension to other 
kinds of genetic variation, such as copy number variation or rare variants [Jakobsson et al., 
2008] may be helpful in determining whether we can expand our knowledge base about 
genetic determinants of PD.
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FIG. 1. 
Forest plot of subgroup summary effects estimates presenting ORs and 95% CIs computed 
by random effects for the replication data and for the original meta-analysis of GWA data.
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